Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Medivir. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Medivir's earnings available for a low price, and how does
this compare to other companies in the same industry?
Medivir is not considered high growth as it is expected to be loss making for the next 1-3 years.
Medivir's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Medivir's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Uli Hacksell, Ph.D., serves as Chief Executive Officer and President of Medivir AB (publ) and served as its Acting Chief Executive Officer since October 15, 2018. He has been Director of Active Biotech AB (publ) since May 23, 2019. He has been Chairman of Adhera Therapeutics, Inc. since July 1, 2018. Dr. Hacksell has been the Chairman of Glionova AB since June 1, 2015. He was Chairman of Cerecor Inc. since May 22, 2015 until April 15, 2019. He has been Director of Cerecor Inc. since May 22, 2015. Dr. Hacksell served as the Chief Executive Officer and President of Cerecor Inc. from January 1, 2016 to August 14, 2017. Dr. Hacksell served as the Chief Executive Officer of ACADIA Pharmaceuticals Inc. from September 2000 to March 11, 2015 and served as its President until March 11, 2015. Dr. Hacksell has over 20 years of international R&D management experience from both large pharmaceutical and biotech companies as well as over 10 years of experience as public company CEO. Dr. Hacksell served as the Chief Financial Officer and Chief Accounting Officer of ACADIA Pharmaceuticals Inc., from April 18, 2014 to July 2014. He served as an Executive Vice President of Drug Discovery of ACADIA from February 1999 to September 2000. From August 1991 to February 1999, Dr. Hacksell held various senior executive positions at Astra, he served as Vice President of Drug Discovery & Technology and President of Astra Draco. From August 1991 to May 1994, he served as Vice President of CNS Preclinical R&D at Astra Arcus. He served as Chairman of SynActPharma A/S until 2015. Dr. Hacksell served as the Chairman of Action Pharma A/S since 2003. Dr. Hacksell serves as a Board Member of SynAct Pharma A/S. He has been a Board Member of InDex Pharmaceuticals AB since June 2015. He has been Director at InDex Pharmaceuticals Holding AB (publ) since 2015. He has been a Director of Medivir AB (publ) since May 3, 2018 and serves as its Acting CEO since October 15, 2018. He serves as a Member of Advisory Board at Medical Products Agency. Dr. Hacksell served as a Director of ActionPharma A/S. He served as a Member of Investment Advisory Board of Karolinska Development AB (publ). Dr. Hacksell served as a Director of SLS Invest. Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. He served as a Director of ACADIA Pharmaceuticals Inc. from September 2000 to March 2015. He has authored about 200 scientific articles. Dr. Hacksell received a Ph.D. in Medicinal Chemistry in 1981, a Master of Pharmacy in 1976 from Uppsala University and holds an MPH.
Insufficient data for Uli to compare compensation growth.
Uli's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Medivir management team is less than 2 years, this suggests a new team.
CEO, President & Director
Chief Financial Officer
Executive VP & COO
Chief Scientific Officer
Chief Medical Officer
Senior Principal Scientist & MIV-818 Project Leader
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Medivir board of directors is less than 3 years, this suggests a new board.
Board of Directors
CEO, President & Director
An van Es-Johansson
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Medivir individual insiders in the past 3 months, but not in substantial volumes.
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.